Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00578825
  4. Details
NCT00578825 Clinical Trial

A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

Severe Acute Respiratory Syndrome Clinical Trial

Official title:
A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT00578825
Other study ID # KW/FR/04-009
Secondary ID HARECCTR0500028N
Status Not yet recruiting
Phase N/A
First received December 20, 2007
Last updated August 21, 2013

Study information
Verified date August 2013
Source Hospital Authority, Hong Kong
Contact Wai Cho Yu, Dr
Phone (852) 2990 3737
Email yuwc@ha.org.hk
Is FDA regulated No
Health authority Hong Kong: Ethics Committee
Study type Interventional

Clinical Trial Summary

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 340
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.

Exclusion Criteria:

- Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Lopinavir / Ritonavir plus Ribavirin

Locations
Country Name City State
China Department of Health Hong Kong
China Kowloon Hospital Hong Kong
China Prince of Wales Hospital Hong Kong
China Princess Margaret Hospital Hong Kong
China Queen Mary Hospital Hong Kong
China The Chinese University of Hong Kong Hong Kong
China The University of Hong Kong Hong Kong
China Tuen Mun Hospital Hong Kong
China United Christian Hospital Hong Kong

Sponsors (1)
Lead Sponsor Collaborator
Hospital Authority, Hong Kong

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Development of severe SARS Any time during the acute illness
Secondary Adverse events Throughout the illness period
Secondary SARS-CoV Viral load Throughout the illness period
Secondary Immunological profile Throughout the illness period
See also
  Status Clinical Trial Phase
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Not yet recruiting NCT04386070 - Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 Phase 3
Withdrawn NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 Phase 3
Withdrawn NCT00073086 - Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS) N/A
Active, not recruiting NCT04527432 - COVID-19 Health Professional Impact Study N/A
Completed NCT00215826 - Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers Phase 2
Completed NCT04366934 - Study of the Pathogenesis of Olfactory Disorders in COVID-19
Completed NCT04402060 - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 Phase 1/Phase 2
Completed NCT04376684 - Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease Phase 2
Completed NCT04395144 - COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss N/A
Completed NCT04357730 - Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection Phase 2
Completed NCT04425213 - Obesity and Mortality of Critically Ill Patients With COVID-19
Completed NCT04425863 - Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
Completed NCT06287554 - Effect of Early Implementation of Prone Positioning
Completed NCT04328129 - Household Transmission Investigation Study for COVID-19 in Tropical Regions N/A
Completed NCT04602351 - Communication in ICU During COVID-19
Completed NCT03225807 - Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure

External Links